Pulmatrix, Inc. Material Event: The Eos SENOLYTIX Merger

If you follow Pulmatrix, Inc. (NASDAQ: PULM), there is major news regarding a fundamental shift in the company’s business focus. Here is the breakdown of the merger agreement and what it means for your investment.

1. What is happening?

On March 26, 2026, Pulmatrix announced a deal to acquire Eos SENOLYTIX, Inc., a private biotech firm focused on "senolytic" therapies—drugs designed to eliminate aging cells linked to chronic diseases.

While structured as a merger, this is effectively a reverse takeover. Once the deal closes in late 2026, Pulmatrix will rebrand as "Eos SENOLYTIX, Inc." To meet Nasdaq’s minimum price requirements, the company also plans a reverse stock split.

2. Why is this happening?

Pulmatrix has faced cash shortages and limited revenue from its legacy drug delivery platform. To keep the lights on until the merger closes, the company is using two funding strategies:

• Bridge Financing: Pulmatrix is issuing $1 million in preferred stock to an Eos affiliate to cover daily operations.
• Eos Capital Injection: Eos is raising $18 million from institutional investors to fund clinical trials for its lead drugs over the next 18–24 months.

3. What this means for your investment

This deal is a total strategic pivot. Pulmatrix is effectively being absorbed by Eos, which changes the nature of your investment:

• Massive Dilution: After the deal closes, current Eos shareholders will own about 94% of the company. Legacy Pulmatrix shareholders will see their ownership reduced to about 6%.
• Governance Shift: Eos will take control of the boardroom, appointing five of the six directors.
• New Business Focus: Your investment is no longer tied to Pulmatrix’s legacy respiratory platform; it is now tied entirely to the success of Eos’s high-risk, high-reward longevity drug pipeline.

4. What to watch for

• The Conversion Price: The $1 million in preferred stock can be converted into common shares at a discount. Keep an eye on the "conversion price" mentioned in future filings, as it determines how many new shares are issued—which could dilute your position even further.
• Operational Risk: Pulmatrix is now essentially a vehicle for Eos to access public markets. The value of your shares will depend entirely on Eos’s ability to move its drugs through clinical trials successfully.
• Volatility: Expect significant price swings as the market adjusts to the new ownership structure and the upcoming reverse stock split.

5. Next Steps

The deal is not final yet. Here is what needs to happen:

1. Stockholder Vote: Pulmatrix shareholders must vote to approve the merger, the name change, and the increase in authorized shares.
2. Regulatory Approval: The SEC must clear the registration statement, and the company must remain compliant with Nasdaq rules.
3. The "Lock-up": To help stabilize the stock, major Eos shareholders have agreed not to sell their new shares for 180 days following the close.

Action Item: Before you make any decisions, head to the SEC’s EDGAR website and search for the latest Proxy Statement filed by Pulmatrix. It will contain the exact exchange ratio and the terms of the reverse stock split, which are the two most important numbers for calculating the future value of your holdings.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Biotech investments carry significant risk—always do your own research or consult with a professional before making investment decisions.